Neurogene Past Earnings Performance
Past criteria checks 2/6
There is insufficient data on Neurogene's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -30.7% |
| Net Margin | 255.6% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Neurogene makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1 | 2 | 17 | 0 |
| 31 Mar 24 | 0 | 9 | 14 | 0 |
| 31 Dec 23 | 0 | 14 | 11 | 0 |
| 30 Sep 23 | 0 | -51 | 11 | 0 |
| 30 Jun 23 | 0 | -49 | 9 | -26 |
| 31 Mar 23 | 0 | -52 | 9 | -13 |
| 31 Dec 22 | 0 | -55 | 9 | 0 |
Quality Earnings: NGNE has a high level of non-cash earnings.
Growing Profit Margin: NGNE became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NGNE has become profitable over the past 5 years.
Accelerating Growth: NGNE has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: NGNE has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: NGNE's Return on Equity (-30.7%) is considered low.